212 Participants Needed

Genetic Testing for Bleeding Disorders

(GT4BD Trial)

Recruiting at 2 trial locations
JG
MC
Overseen ByMegan Chaigneau, RN
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Queen's University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you are taking medications known to cause bleeding, you may be excluded from participating.

What data supports the effectiveness of genetic testing for inherited bleeding disorders as a treatment?

Genetic testing for inherited bleeding disorders is effective because it helps confirm diagnoses, distinguishes between similar conditions, and identifies genetic causes of bleeding, which can improve clinical care and treatment decisions. Advances in genetic testing technology, like next generation sequencing, allow for accurate identification of bleeding disorders, making it a valuable tool in diagnosing and managing these conditions.12345

Is genetic testing for bleeding disorders safe for humans?

Genetic testing for bleeding disorders is generally considered safe, as it involves analyzing DNA to confirm diagnoses and identify genetic mutations. It does not involve the use of medications or treatments that could cause adverse effects.14678

How does genetic testing for bleeding disorders differ from other treatments?

Genetic testing for bleeding disorders is unique because it focuses on identifying the underlying genetic causes of the condition, which can lead to a more accurate diagnosis and personalized treatment plan. Unlike traditional methods that rely on clinical assessments and lab tests, genetic testing can detect specific genetic mutations and help in genetic counseling and prenatal diagnosis.12359

What is the purpose of this trial?

The investigators aim to test the introduction of genomic testing early in the diagnostic pathway for inherited bleeding disorders in patients who have not received a diagnosis after first-line testing.The goal of this clinical trial is to test the introduction of genomic testing early in the diagnostic pathway for patients referred to Hematology for a suspected inherited bleeding disorder. The main questions it aims to answer are:1. Does adding early genomic testing increase the number of patients who are diagnosed?2. Does adding early genomic testing decrease the overall time to diagnosis?3. Is it cost-effective to include early genomic testing in the diagnostic pathway?The investigators will compare with a control group of participants who are receiving standard care (no early genomic testing).Participants will randomized to a standardized diagnostic testing plus early genomic testing group or to the standardized diagnostic testing group only (with the possibility of being offered genomic testing after 1 year in the study).

Research Team

PD

Paula D James, MD, FRCPC

Principal Investigator

Queen's University

Eligibility Criteria

This trial is for patients with suspected inherited bleeding disorders who haven't been diagnosed after initial tests. It's open to those referred to Hematology and requires participants not yet having a confirmed diagnosis of their condition.

Inclusion Criteria

I am seeing a doctor because I have abnormal bleeding.
I have a history of abnormal bleeding, confirmed by a specialist.

Exclusion Criteria

I have been diagnosed with a hereditary bleeding disorder.
I have a bleeding condition due to medication or liver/kidney disease.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Diagnostic Testing

Participants undergo standard diagnostic testing with or without early genomic testing

1 year
Multiple visits as needed for diagnostic testing

Follow-up

Participants are monitored for diagnostic outcomes and health-related quality of life

1 year
Regular follow-up visits to assess outcomes

Economic Analysis

Economic implications and cost-effectiveness of genomic testing are analyzed

2 years

Treatment Details

Interventions

  • Genetic testing for inherited bleeding disorders
Trial Overview The study is examining if early genomic testing can help diagnose inherited bleeding disorders faster and more effectively compared to standard care. Participants are randomly assigned to either receive early genomic testing along with standard diagnostic tests or just the standard tests, with a later option for genomic testing.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Early Genomic Testing Diagnostic PathwayExperimental Treatment1 Intervention
Participants will receive early genomic testing in addition to standard diagnostic testing.
Group II: Standard Diagnostic PathwayActive Control1 Intervention
Participants will receive standard diagnostic testing with the option of receiving genomic testing after 12 months.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Queen's University

Lead Sponsor

Trials
382
Recruited
122,000+

Queen's University

Lead Sponsor

Kingston Health Sciences Centre

Lead Sponsor

Trials
312
Recruited
112,000+

The Ottawa Hospital

Collaborator

Trials
97
Recruited
64,000+

Unity Health Toronto

Collaborator

Trials
572
Recruited
470,000+

References

Molecular testing for disorders of hemostasis. [2021]
Diagnosis of haemophilia and other inherited bleeding disorders - Is a new paradigm needed? [2021]
Diagnosis of inherited bleeding disorders in the genomic era. [2021]
Patient-reported outcomes in autosomal inherited bleeding disorders: A systematic literature review. [2022]
Hemophilia: a practical approach to genetic testing. [2013]
Safety surveillance in haemophilia and allied disorders. [2017]
Inherited bleeding disorders: results from the Italian Regional Haemophilia Centre of Pescara. [2021]
Genetic sequence analysis of inherited bleeding diseases. [2022]
Genetics of haemostasis. [2012]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security